SHANGHAI, China, July 27, 2026
IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the company’s first-in-class (FIC) CEACAM5-targeted dual-payload antibody-drug conjugate (ADC) developed using its proprietary branched linker dual-payload ADC platform. IMP3201 combines Exatecan (topoisomerase I inhibitor) with the company’s proprietary ATR inhibitor (ATRi) at an optimized molar ratio to simultaneously induce DNA damage while blocking DNA damage repair, generating synergistic anti-tumor activity. The investigational therapy is being developed for the treatment of gastrointestinal malignancies, including colorectal cancer, pancreatic cancer, gastric cancer, and esophageal squamous cell carcinoma, addressing significant unmet clinical needs in patients with advanced cancers.
Dual-Payload ADC Designed to Overcome Drug Resistance
Unlike conventional single-payload ADCs, IMP3201 utilizes a dual-payload strategy that delivers both a topoisomerase I inhibitor and an ATR inhibitor directly to CEACAM5-expressing tumor cells. According to the company, this dual mechanism enhances anti-tumor efficacy by simultaneously damaging cancer cell DNA while preventing tumor cells from repairing that damage, helping overcome tumor insensitivity and acquired resistance commonly associated with TOPO inhibitor-based therapies. Preclinical studies demonstrated significantly improved in vitro and in vivo anti-tumor activity, together with a favorable therapeutic window, supported by precise tumor targeting, stable systemic circulation, and controlled payload release. The technology is intended to improve treatment outcomes across multiple difficult-to-treat gastrointestinal cancers.
CEACAM5 Emerges as Promising ADC Target in Solid Tumors
CEACAM5, also known as carcinoembryonic antigen (CEA/CD66e), is a highly expressed tumor-associated antigen found in several epithelial-derived cancers, including colorectal, gastric, pancreatic, esophageal, and non-small cell lung cancers, while maintaining limited expression in healthy adult tissues. The protein plays an important role in tumor progression, metastasis, and resistance to cell death, making it an attractive therapeutic target for next-generation ADCs. IMPACT Therapeutics noted that other CEACAM5-targeted ADCs, including Merck’s M9140, have already advanced into Phase 2/3 clinical development, supporting growing industry interest in the target. By combining CEACAM5 targeting with a dual-payload design, IMP3201 aims to deliver stronger and more durable anti-cancer activity than existing single-payload ADC approaches.
Advertisement
IMPACT Expands Next-Generation ADC Innovation Platform
The nomination of IMP3201 represents an important milestone for IMPACT Therapeutics, validating the productivity of its proprietary dual-payload ADC platform while expanding the company’s growing precision oncology portfolio. In addition to commercial-stage PARP inhibitors and multiple synthetic lethality-based therapies, the company has established a comprehensive ADC pipeline incorporating both single-payload and dual-payload technologies designed to address drug resistance and improve therapeutic efficacy. By leveraging its integrated research platform across small molecules, ADCs, and targeted degraders, IMPACT aims to accelerate the development of innovative cancer therapies capable of addressing unmet medical needs across gastrointestinal and other solid tumors while strengthening its position in the rapidly expanding global ADC market.
Source: IMPACT Therapeutics,press release
